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Abstract 
The investigation deals with the influence of permeation of rutin from carboxymethyl cellulose gel through 
full-thickness pig ear skin by (S)- and (R)-alaptide as potential excipients. Alaptide, 8-methyl-6,9-
diazaspiro[4.5]decan-7,10-dione, is the original Czech compound. By means of this rapid screening it was 
found out that the permeation of rutin through the skin increased linearly with time and was enhanced by 
both enantiomers of alaptide: approx. 1.2-fold by (R)-alaptide and approx. 1.5-fold by (S)-alaptide. 
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Introduction 
Permeation modifiers (enhancers and retardants) affect the barrier properties of the skin. Chemical 
permeation enhancers (CPEs) are employed to increase the transdermal penetration of therapeutic agents 
[1−6 and refs. therein]. Alaptide, (S)-8-methyl-6,9-diazaspiro[4.5]decan-7,10-dione (see Fig. 1) was designed 
as an analogue of melanocyte-stimulating hormone release-inhibiting factor (MIF-1) [7−10] and thus is able 
to influence the creation and function of keratinocytes [11−13]. Based on these facts and structural analogy 
with other CPEs [4], it was suggested to investigate alaptide as a potential CPE of many anti-inflammatory 
drugs, antimicrobial chemotherapeutics, sex hormones/genital system modulators or drugs of 
central/vegetative nervous system [14−16]. Permeation through the skin of micronized and nanonized  
(S)-alaptide from semisolid formulations was investigated recently [17], and the transdermal modifying 
effect of micronized and nanonized (S)-alaptide was also described [14−16,18,19]. It was found that 
enhancers can become retardants in different formulation environments or when different particle sizes 
were used and vice versa. Since modifiers influence drug delivery, further exploration of these compounds 
is required to understand their modifying action on the properties of the skin. 
Today more than 50 % of marketed drugs are chiral. It has been well recognized that the 
stereochemistry of chiral drugs has a major influence on their pharmacological, pharmacokinetic and 
toxicological actions. Studies on enantiomeric differences in the percutaneous permeation of chiral 
compounds have been actively pursued in recent years. Stratum corneum, the rate-limiting barrier in 
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transdermal permeation, is made up mainly of keratin and ceramides, which could potentially provide 
chiral environment. Transdermal delivery is facilitated by the presence of penetration enhancers, which act 
primarily by altering the diffusion by disrupting the highly ordered membrane structure or by affecting the 
partitioning behaviour of the diffusant molecules. Enantioselective permeation was observed with some 
chiral excipients, including, for example, terpene enhancers [20−22]. 
Based on the above mentioned facts and the excellent enhancement effect of (S)-alaptide [14−16],  
(R)-alaptide was prepared, and both enantiomers were tested by means of rapid screening for their ability 
to modify the skin barrier properties. Bioflavonoid glycoside rutin, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-
oxo-4H-chromen-3-yl 6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside, see Fig. 1, was chosen as an 
model compound, since rutin is one of the most often used drugs for decreasing capillary permeability and 
for treatment of haemorrhoids, varicosis and microangiopathy [23]. Enhanced permeation through the skin 
and higher availability of the compound would be favourable for the treatment of vascular wall fragility. 
Within this study the permeation of rutin from carboxymethyl cellulose gel and subsequently the 
permeation of rutin with the addition of the individual enantiomers of alaptide as modifiers of transdermal 
permeation from the same formulation are investigated. 
Flavonoids (bioflavonoids, Vitamin P) are a class of plant secondary phenolic metabolites. Today more 
than 4000 flavonoid-based compounds were described [24,25]. Flavonoids are glycosides containing 
aglycone derived from benzopyran (chromene) with lateral phenyl in the positions C(2), C(3) or C(4) of the 
benzopyran scaffold. The phenyl rings are marked A and B, and the pyran ring C is ortho-condensed with 
the ring A. In nature flavonoids are substituted (especially in position 3 of the benzopyran scaffold) by 
various sugars and generate flavonoid glycoside. Aglycone or the glycosyl group can be substituted by a 
hydroxyacid [25,26]. Both aglycone and glycosides have biological effects. Bioflavonoids normalize 
permeability of capillaries and remove their fragility; they have antihaemorrhagic and anti-edematous 
effects [25−28]. Also antibacterial, antioxidant and anti-inflammatory activities are typical for them [25−28]. 
Bioflavonoids are used as venopharmaceuticals, i.e. drugs for the treatment of chronic venous insufficiency, 
superficial thrombophlebitis and haemorrhoids. They can be applied locally for the treatment of 
dermatomicroangiopathy, periphlebitis, haematomas and traumatic oedema [28]. 
 
Figure 1. Structures of investigated compounds. 
Experimental 
Preparation of alaptide 
Both alaptide enantiomers were synthesized by the standard process [29] and characterized [30]. The 
specific optical rotation of 0.2 mol/L methanolic solution is [α]D
20 = +21.2° for the (R)-enantiomer and 
[α]D
20 = -21.2° for the (S)-enantiomer. The melting point of (S)-alaptide is 232-234 °C, while that of  
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(R)-alaptide is 230-232 °C. Rutin was purchased from Sigma, all other reagents were purchased from Aldrich 
and Lach-Ner. 
Investigated Semisolid Formulations 
The composition of gel with 10% (w/w) rutin was the following: rutin 10 g and carboxymethyl cellulose 
gel (carboxymethyl cellulose sodium 5 g, macrogol 300 10 g, propylene glycol 2.5 g, methylparaben 0.2 g, 
propylparaben 0.2 g and purified water 87.3 g) up to 100 g. The composition of gel with the addition of 
alaptide 1% (w/w; in relation to rutin amount) was the following: rutin 10 g, alaptide 0.1 g and 
carboxymethyl cellulose gel up to 100 g. 
In vitro transdermal permeation experiments 
Skin samples were obtained from porcine ear. Full thickness skin was cut in fragments and stored at 
−20 °C until utilized. Skin samples were slowly thawed (at 4 °C overnight and then at ambient temperature) 
before each experiment. The permeation enhancing effect of both alaptide enantiomers was evaluated in 
vitro, using a vertical Franz diffusion cell (SES – Analytical Systems, Germany) with a donor surface area of 
0.6359 cm2 and a receptor volume of 5.2 mL. The skin was mounted between the donor and receptor 
compartments of the Franz diffusion cell with the epidermal side up. The receptor compartment was filled 
with phosphate buffered saline (pH 7.4) and maintained at 34.0±0.5 °C, using a circulating water bath. The 
receptor compartment content was continuously stirred using a magnetic stirring bar. The skin was kept in 
contact with the receptor phase for 0.5 h prior to the experiment. The investigated gel formulations were 
applied to the skin surface as a donor sample, and the donor compartment of the cell was covered by 
Parafilm®. Samples (0.5 mL) of the receptor phase were withdrawn at five pre-determined time intervals 
(30, 60, 90, 120 and 180 min), and the cell was refilled with an equivalent amount of fresh buffer solution. A 
minimum of five determinations was performed using skin fragments from a minimum of 2 animals for 
each compound, and the data was expressed as means ± SD. The samples were immediately analysed by 
HPLC. 
The analysis of the samples was performed using an Agilent 1200 series HPLC system, equipped with a 
diode array detection (DAD) system, a quaternary model pump and an automatic injector (Agilent 
Technologies, Germany). Data acquisition was performed using ChemStation chromatography software. A 
Zorbax Eclipse XDB C18 5 μm, 4.6×150 mm (Agilent, USA) chromatographic column was used. The total flow 
of the column was 0.5 mL/min; injection was 10 μL; column temperature was 30 °C; and sample 
temperature was 10 °C. The detection wavelength of 254 nm was chosen; the time of analysis was 10 min. 
A mixture of MeOH (HPLC grade, 85.0 %) and H2O (HPLC – Mili-Q Grade, 15.0%) was used as a mobile 
phase. The retention time (tR) of rutin was 3.70±0.05 min; the limit of detection (LOD) was 0.99 ng/mL; and 
the limit of quantification (LOQ) was 3.3 ng/mL. 
Results and Discussion 
Rutin was chosen as a frequently applied venopharmaceutical for the topical treatment of the fragility of 
vascular wall that can be associated with various injuries of the skin, because alaptide itself shows 
significant curative effect on the skin [8,31]. The rapid in vitro skin permeation screening experiments were 
performed using static Franz diffusion cells [32] within 3 hours only. Full-thickness pig ear skin was selected 
for in vitro evaluation of permeation. This tissue is a suitable in vitro model of human skin [33], because 
porcine skin has shown to be histologically and biochemically similar to human skin, and it has been used in 
numerous studies [4]. The permeation of rutin through full-thickness pig ear skin without and with 1 % 
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(w/w related to rutin) (S)- or (R)-enantiomer of alaptide was tested from carboxymethyl cellulose gel as a 
donor vehicle. All the results are provided in Table 1 and illustrated in Figure 2. 
Table 1. Cumulative permeated amounts Qt per unit area [μg/cm
2
] of rutin from carboxymethyl cellulose gel without 
and with (S)-alaptide or (R)-alaptide as modifiers of transdermal permeation achieved in in vitro transdermal 
permeation experiments using Franz diffusion cell. Qt are expressed as mean ± SD (n = 5 experiments). 
Time [h] 
Cumulative permeated amounts Qt per unit area[µg/cm
2] 
rutin rutin+(S)-alaptide rutin+(R)-alaptide 
0.5 3.7±0.6 5.5±0.7 4.6±0.6 
1.0 6.5±0.7 9.7±0.9 7.7±0.8 
1.5 9.0±0.5 15.4±1.0 11.9±1.0 
2.0 13.2±1.1 19.4±1.2 15.1±0.8 


















rut rut+SALA rut+RALA  
Figure 2. In vitro profile of cumulative permeated amounts Qt per unit area [μg/cm
2
] in time of rutin 
(rut) alone and after addition of 1 % w/w of (S)-alaptide (SALA) or (R)-alaptide (RALA) from 
carboxymethyl cellulose gel through skin. Qt values are expressed as mean ± SD (n = 5 experiments). 
As the presented study represents a preliminary rapid in vitro screening, all the experiments were 
performed only in the time range from 0.5 to 3.0 h. The values obtained from the permeation experiments 
were expressed as the cumulative permeated amount of the drug (Qt [μg]) per unit of skin surface area 
(0.6359 cm2), see Table 1. Due to the short time interval of experiments steady-state permeation flux and 
lag time cannot be calculated, but this was not the aim of the experiments. The dependences of the 
cumulative permeated amount of the drug per unit of skin surface area in time (Qt versus t) are shown in 
Figure 2. Based on the results it can be stated that permeation of rutin through the skin increased linearly 
with time; for rutin alone correlation coefficient was r = 0.9891 and slope 5.95 /cm2/h; for rutin with  
(R)-alaptide r = 0.9896 and slope 7.16 /cm2/h; and for rutin with (S)-alaptide r = 0.9915 and slope 
9.21 /cm2/h. Based on the ratios slopes of the linear dependences Qt versus t permeation enhancement 
within the studied time span (up to 3 h) can be evaluated. The permeation of rutin with (R)-alaptide was 
1.22-fold higher than without the addition of (R)-alaptide. The addition of (S)-alaptide to 
carboxymethyl cellulose gel caused 1.54-fold higher permeation of rutin through the skin than from the 
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formulation without (S)-alaptide. On the other hand, rutin permeated from the formulation containing  
(S)-alaptide only 1.27-fold more compared with (R)-alaptide. 
As mentioned above the components of stratum corneum form a chiral environment, therefore there is 
potential for stereoselective interactions of an enhancer with skin components. Stereoselective interactions 
of individual drug enantiomers (e.g., propranolol, metoprolol, timolol, ketorolac, ketoprofen, flurbiprofen, 
ephedrine, oxybutynin, amlodipine) with the skin components involving different permeation rates of 
individual enantiomers through the skin were tested. Some authors found different permeation rates for 
enantiomers, while other studies showed no enantiomeric differences in the permeation [20−22,34−36]. 
Similarly, investigations of interactions of individual CPE enantiomers with the skin provided opposite 
results [20,22,37,38]; therefore additional studies are needed to be performed to answer whether the skin 
is an enantioselective membrane and given its mechanism of action, enhancer conformation can influence 
its enhancing properties or the differences in the permeation rates between the individual enantiomers are 
not related to any stereoselective interactions, but they can be explained only by different physicochemical 
properties. 
Conclusions 
The ability of (S)- and (R)-alaptide to modify the permeation of rutin through the porcine ear skin was 
examined using the Franz cell in the rapid in vitro screening. Both enantiomers of alaptide applied in 
concentration 1 % w/w related to the amount of rutin influenced the permeation of the drug from the 
carboxymethyl cellulose gel through the skin. According to the calculated cumulative permeated amount of 
the drug per unit of skin surface area in time, rutin with addition of the (R)-enantiomer of alaptide 
permeated 1.22-fold more than from the formulation without the alaptide enantiomers, and with addition 
of the (S)-enantiomer of alaptide permeated 1.54-fold more than without the alaptide enantiomers. The 
permeation of rutin through the skin increased approximately linearly with time. It can be concluded that 
the presence of alaptide facilitated permeation of rutin. 
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